29 May, EOD - Indian

SENSEX 81633.02 (0.39)

Nifty 50 24833.6 (0.33)

Nifty Bank 55546.05 (0.23)

Nifty IT 37754.15 (0.77)

Nifty Midcap 100 57457.25 (0.55)

Nifty Next 50 67093.8 (0.15)

Nifty Pharma 21589.35 (0.92)

Nifty Smallcap 100 17889.4 (0.59)

29 May, EOD - Global

NIKKEI 225 37923.02 (-1.33)

HANG SENG 23573.38 (1.35)

S&P 5920.25 (-0.24)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(26 Nov 2024, 12:47)

Akums Drugs ties up with Jagdale Inds for marketing of ready-to-drink nutritional beverages

Akums Drugs and Pharmaceuticals said that its wholly owned subsidiary Maxcure Nutravedics has entered into a collaboration agreement with Jagdale Industries for marketing of ready-to-drink nutritional beverages.


This collaboration exclusively focuses on aseptic manufacturing and subsequent filling in carton packing for the ready-to-drink (RTD) market, targeting an expansive array of health and wellness products.

The electrolyte RTD market in India, valued at over Rs 1,000 crore with more than 150 million packs sold annually, is experiencing robust growth.

With a steady 10% annual increase in volume, this market sees heightened demand, particularly during the summer months, when hydration needs peak.

Simultaneously, the broader Indian RTD market is witnessing significant expansion, driven by a rising preference for functional beverages, therapeutic drinks, and wellness products.

Aseptic carton packing technology is at the forefront of this evolution. It ensures the highest standards of safety, shelf stability, and nutrient retention, meeting the evolving needs of modern consumers.

Sanjeev Jain, managing director of Akums Drugs & Pharmaceuticals, said: “With this partnership, Akums and Jagdale will deliver products that seamlessly integrate health benefits with superior Aseptic packaging technology.”

Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

The pharma company consolidated net profit spiked 104.96% to Rs 65.20 crore despite of 12.54% declined in revenue from operations to Rs 1,033.1 crore in Q2 FY25 over Q2 FY24.

The scrip shed 0.98% to currently trade at Rs 665.80 on the BSE.


More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +